Skip to main content
Premium Trial:

Request an Annual Quote

Natera to Raise $250M in Follow-on Stock Offering

NEW YORK – Natera said on Wednesday that it has launched a follow-on public offering of $250 million of shares of its common stock.

In a shelf registration statement filed with the US Securities and Exchange Commission, Natera said that at an assumed public offering price of $61.79 per share, the last reported sale price of its common stock on Sept. 8, it would be offering 4,045,962 shares of its common stock.

Natera also expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million worth of shares of its common stock at the public offering price, less the underwriting discounts and commissions.

JP Morgan, Morgan Stanley, Cowen, and SVB Leerink are acting as joint book-running managers for the offering, while Baird and Craig-Hallum Capital Group are acting as co-managers.

In April, Natera had offered $250 million worth of convertible senior notes.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.